The landscape of Menin inhibition in acute myeloid leukemia (AML) continues to evolve rapidly, with several competitors vying for position in this emerging therapeutic niche. At this year’s American Society of Hematology (ASH) meeting in San Diego, we saw important updates presented across the field, which shed new light on both the potential and challenges of targeting the Menin-MLL interaction in advanced disease.

San Diego street art

The therapeutic goals in advanced AML have always been clear – achieve deep remissions, bridge to transplant where possible, and ultimately extend survival. What makes the Menin inhibitor story particularly compelling is how these agents are reshaping our expectations for molecularly targeted therapy in AML, especially in difficult to treat populations harbouring KMT2A rearrangements or NPM1 mutations.

What’s also particularly striking about this year’s updates is the emerging differentiation between compounds in the class. While all share the core mechanism of disrupting the Menin-MLL interaction, we’re beginning to see distinct profiles emerge in terms of efficacy, safety, and potential positioning.

The battle lines are being drawn in what promises to be a fascinating commercial race as more clinical data become available over time.

In our latest review, we assess how revumenib, bleximenib, enzomenib, and ziftomenib are shaking out in the relapsed/refractory (R/R) setting and also take a look at ziftomenib and bleximenib in newly diagnosed AML…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by